Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
Suchergebnisse
Alles
-
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
-
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
-
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
-
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
-
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market
-
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
-
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference....